Разместить пресс-релиз можно только после бесплатной регистрации. Добавить новость на наш сайт БЕСПЛАТНО


 
07/12/2017 10:18

Market Research Reports

Bacterial Vaginosis Drugs Market Share, Market Analysis, Industry Size, Strategies and Forecast 2017 - 2025

Версия для печати pdf-версия

The latest market report published by Credence Research, Inc. “Bacterial Vaginosis Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 - 2025,” the global bacterial vaginosis drugs market is set to grow at a CAGR of 2.9 % from 2017 to 2025.

Market Insights

The microflora imbalance due to the substitution of hydrogen peroxide producing Lactobacilli sp., with that of harmful bacterial species such as G.vaginalis, Mycoplasma and Ureaplasma causes bacterial vaginosis. It is very important to understand that few women experience the infection for a longer period of time and some for a transient period. The whiff test is used for the diagnosis of bacterial vaginosis which is asymptomatic in most cases. The recent approval of SPL7013 an astrodimer sodium is used for the treatment of recurring bacterial vaginosis due to is antiviral properties. Secnidazole (Solosec) is set to replace metronidazole as a single dose to be taken once in day orally. The granules are sprinkled over yogurt, pudding or apple sauce and consumed within 30 minutes without chewing the granules.

Browse the full report Bacterial Vaginosis Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/bacterial-vaginosis-drugs-market

Metronidazole and clindamycin are prescribed by physicians globally as the first line of treatment in bacterial vaginosis. The dominance of antibiotics is backed by a reason that the generic antibiotics available are both oral and topical formulations at affordable prices. Normal pH retention gels will highlight quick acceptance owing to its nontoxicity and immediate symptomatic relief.

Dominance of North America in the bacterial vaginosis drugs market has been related to the rising prevalence of bacterial vaginosis in non-white women due to unsafe sex, and poor lifestyle such as binge drinking and incessant cigarette smoking. The presence of established generic market for antibiotic drugs, and lack of knowledge regarding self hygiene will project an impressive growth for bacterial drugs market in Asia Pacific.

The bacterial vaginosis drugs market includes major players such as Pfizer, Inc., Bayer AG, Mylan N.V., Novartis AG, Abbott Laboratories, Inc., Symbiomix Therapeutics, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited and Perrigo Company Plc.

Browse the full report Bacterial Vaginosis Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/bacterial-vaginosis-drugs-market

Key Market Movements:

Rising prevalence of bacterial vaginosis in women from 18-44 years age group
In the near future product pipeline will address problems such as antibiotic resistance and recurrence of bacterial vaginosis
Recently FDA approved drug formulations such as Solosec and VivaGel that will drive the bacterial vaginosis drugs market

Latest Report

Smart Wallets Market to Reach US$ 526.8 Mn by 2025

https://www.credenceresearch.com/report/smart-wallets-market

Life Science Microscopy Devices Market To Reach Worth US$1,808.2 Mn By 2025

https://www.credenceresearch.com/report/lifescience-microscopy-market

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact:

Name: Chris Smith

Designation: Global Sales Manager

Ph: 1-800-361-8290

Email: sales@credenceresearch.com

Web: http://www.credenceresearch.com/

EMEAPR.com » Маркетинг, реклама и PR